Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
AIMS/HYPOTHESIS: The aim of the study was to examine the 48 month outcome of treating recent-onset type 1 diabetic patients for 6 days with humanised CD3-antibody, ChAglyCD3. METHODS: Eighty patients, aged 12-39 years, were recruited for a phase 2 multicentre trial and randomised to placebo (n=40) o...
Hlavní autoři: | Keymeulen, B, Walter, M, Mathieu, C, Kaufman, L, Gorus, F, Hilbrands, R, Vandemeulebroucke, E, Van de Velde, U, Crenier, L, De Block, C, Candon, S, Waldmann, H, Ziegler, A, Chatenoud, L, Pipeleers, D |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
2010
|
Podobné jednotky
-
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Autor: Keymeulen, B, a další
Vydáno: (2005) -
Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients.
Autor: Alkemade, G, a další
Vydáno: (2011) -
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.
Autor: Keymeulen, B, a další
Vydáno: (2010) -
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes.
Autor: Hale, G, a další
Vydáno: (2010) -
The MicroRNA Landscape of Acute Beta Cell Destruction in Type 1 Diabetic Recipients of Intraportal Islet Grafts
Autor: Geert A. Martens, a další
Vydáno: (2021-07-01)